We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The investigational IL-17A and IL-17F inhibitor ...

Let's talk about pollution and five countries in Asia. Or, more specifically, let's talk about the study that people like to cite from 2015 claiming that five countries in Asia — China, Indonesia, the ...

Chronic plaque psoriasis is a condition in which epithelial cells are over produced and form a well-defined site. The redness is often covered with silvery scales of skin. The cause of this type of ...

There’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and UCB’s contender bimekizumab is shaping up for a challenge with another set of ...

The BE SURE study, comparing bimekizumab to Humira® (adalimumab) for the treatment of adults with moderate-to-severe plaque psoriasis, met all co-primary and ranked secondary endpoints BE SURE is the ...

A-SURE is the largest prospective, non-interventional study on the effect of extended half-life factors in haemophilia A, and directly compared Elocta with SHL factors STOCKHOLM, July 13, 2022 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Researchers at AAD VMX 2021 presented the results of the ...

BRUSSELS, Dec. 6, 2019 /PRNewswire/ -- Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive results from the Phase 3 active-controlled BE SURE ...